Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07356505Recruiting
Micra AV2 pacemaker study for heart block
This study tests a small pacemaker, the Micra AV2, for people with a type of heart block that affects electrical signals between the upper and lower heart chambers. The goal is to see how well and safely the device works.
Leuven, Flemish BrabantAges 18 years+ - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT06848582Recruiting
NK cell therapy for high-risk pediatric soft tissue sarcoma
This trial tests whether giving immune cells called NK cells from donated umbilical cord blood can help children and teens with high-risk or returning soft tissue sarcoma. The goal is to see if it is safe and effective when other treatments have been tried.
Guangzhou, GuangdongAges Up to 18 years - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT06850480RecruitingPhase 3
Study of JP-1366 tablets for heartburn and acid reflux
This trial tests a new medication, JP-1366, for people with reflux esophagitis (damage to the esophagus from stomach acid). It aims to see if the drug is safe and effective at healing the esophagus and relieving symptoms like heartburn and regurgitation.
Beijing, Beijing MunicipalityAges 18–75 - NCT05407792Recruiting
Long-term tablets to help bronchiectasis flare-ups
This trial studies whether long-term Staphylococcus albicans tablets can safely reduce bronchiectasis flare-ups and improve symptoms. It may help people with frequent infections/attacks due to bronchiectasis.
Jinan, ShandongAges 18 years+ - NCT06503237Recruiting
SWK002 for tough-to-treat rheumatoid arthritis
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
Changsha, HunanAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06855485Recruiting
Stent for pancreatic pseudocyst drainage study
This trial tests a new stent device (HANAROSTEN® HOT Plumber™ with Z-EUSIT™) to drain fluid collections in the pancreas. It may help if you have a pancreatic pseudocyst or walled-off necrosis with mostly fluid content.
Seoul, SeoulAges 18 years+ - NCT06241482Recruiting
Enhanced recovery after brain surgery in intensive care
This study tests a special recovery program for people with serious brain injuries or strokes who need intensive care. The program focuses on helping you heal faster after surgery.
ShanghaiAges 18–75 - NCT07348640RecruitingPhase 3
Study of new MRI dye for blocked blood vessels
This trial tests a new MRI contrast dye (gadopiclenol) to see if it works as well as the standard dye for finding blocked or narrowed blood vessels. If you have symptoms of vascular disease, you may be able to join and help compare the two dyes.
Birmingham, AlabamaAges 18 years+ - NCT07348302RecruitingPhase 3
Allergy tablet for dust mite rhinitis and asthma
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
Nueve de Julio, Buenos AiresAges 12–65 - NCT07349524RecruitingPhase 2
A study of an oral tablet for COPD
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
Guangzhou, GuangdongAges 40–80 - NCT06856356Recruiting
Robot-assisted knee replacement surgery study
This study tests if robot-assisted total knee replacement surgery is safe and effective. It may help people who need knee replacement surgery by using advanced technology for more precise implant placement.
Hefei, AnhuiAges 18–80 - NCT07348016Recruiting
Platelet-rich plasma and steroid injection for shoulder surgery
This trial tests if adding a combination of platelet-rich plasma (a concentrate from your own blood that may help healing) and a steroid (to reduce inflammation) during arthroscopic surgery improves recovery for people with a torn rotator cuff and a stiff, stuck shoulder.
Nanchang, JiangxiAges 18–70 - NCT07346079RecruitingPhase 4
Corticotropin gel for acute gout flares
This study tests two doses of a medicine called Purified Cortrophin Gel for people having a gout flare that started in the last 5 days. It might be an option if other treatments haven't worked or aren't safe for you.
Boston, MassachusettsAges 18–90 - NCT07343791RecruitingEarly Phase 1
DC-CIK cell therapy plus three drugs for advanced colorectal cancer
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT07346378Recruiting
Brain stimulation for post-stroke aphasia
This study tests a new type of brain stimulation called temporal interference stimulation to see if it can safely help people recover language abilities after a stroke. It aims to improve communication for people with post-stroke aphasia.
Hefei, AnhuiAges 18–80 - NCT07345728Recruiting
BAFFR CAR-T therapy for relapsed B-cell lymphoma
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
WuhanAges 18–78 - NCT07347990Recruiting
Iptacopan for high-risk TA-TMA after stem cell transplant
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Hangzhou, ChinaAges 12 years+ - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT07343635Recruiting
Anti-inflammatory therapy with yellow light for rosacea
This trial tests a combination of an anti-inflammatory gel (Hirudoid), yellow light therapy, and two oral medications (tofacitinib and doxycycline) for Chinese adults with mild to moderate rosacea that causes redness and visible blood vessels. The goal is to see if this approach reduces symptoms safely.
Yiwu, ZhejiangAges 18–70 - NCT07349043RecruitingPhase 1
Spray chemotherapy for colon cancer spread in the belly
This trial tests a new way to give chemotherapy by spraying it into the belly during a minimally invasive surgery. It is for people whose colon or rectal cancer has spread inside the belly (peritoneal metastasis) but not to other organs.
Hangzhou, Other (Non U.s.)Ages 18–75 - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.